Jinling Pharmaceutical, Nanjing Gulou Hospital, and CD16a Tech‑Transfer Deal Bolsters NK‑Cell Oncology
CompanyDeals

Jinling Pharmaceutical, Nanjing Gulou Hospital, and CD16a Tech‑Transfer Deal Bolsters NK‑Cell Oncology

Jacobio Pharma, Oceanpine Capital and Partner Acquire Majority of Jacoray, Fuelling Early‑Stage Cardio‑Oncology R&D
CompanyDeals

Jacobio Pharma, Oceanpine Capital and Partner Acquire Majority of Jacoray, Fuelling Early‑Stage Cardio‑Oncology R&D

Walvax Biotechnology & Pharmaniaga Lifescience Forge Malaysia Partnership for PCV‑13 Production and Distribution
CompanyDeals

Walvax Biotechnology & Pharmaniaga Lifescience Forge Malaysia Partnership for PCV‑13 Production and Distribution

Shandong Buchang’s Luzhou Unit Moves to Secure Exclusive Distribution of Epo‑IgG Fusion in Vietnam
CompanyDeals

Shandong Buchang’s Luzhou Unit Moves to Secure Exclusive Distribution of Epo‑IgG Fusion in Vietnam

AnkeBio and PersonGen Ink Capital‑Increase Deal, Secure Exclusive Greater‑China Agency for PA3‑17 CAR‑T Therapy
Others

AnkeBio and PersonGen Ink Capital‑Increase Deal, Secure Exclusive Greater‑China Agency for PA3‑17 CAR‑T Therapy

Chongqing Precision Biotech Wins NMPA Approval for pCAR‑19B – China’s First Humanised CD19 CAR‑T Therapy for Pediatric B‑ALL
CompanyDrug

Chongqing Precision Biotech Wins NMPA Approval for pCAR‑19B – China’s First Humanised CD19 CAR‑T Therapy for Pediatric B‑ALL

Laekna and Qilu Pharma Sign Exclusive China License for AKT Inhibitor LAE002 (Afuresertib)
CompanyDeals

Laekna and Qilu Pharma Sign Exclusive China License for AKT Inhibitor LAE002 (Afuresertib)

NMPA Grants Marketing Authorisation to Hefei Amvite’s Memantine Hydrochloride ODT for Alzheimer’s Disease
CompanyDrug

NMPA Grants Marketing Authorisation to Hefei Amvite’s Memantine Hydrochloride ODT for Alzheimer’s Disease

Shanghai Henlius Biotech Secures UK MHRA Approval for Denosumab Biosimilars BILDYOS & BILPREVDA
CompanyDrug

Shanghai Henlius Biotech Secures UK MHRA Approval for Denosumab Biosimilars BILDYOS & BILPREVDA

Novo Nordisk Announces Major China Business Restructuring Effective Jan 1 2026
Company

Novo Nordisk Announces Major China Business Restructuring Effective Jan 1 2026

Huadong Medicine Files NDA for Roflumilast Cream (ZORYVE) – First PDE‑4 Topical for Atopic Dermatitis in Greater China
CompanyDrug

Huadong Medicine Files NDA for Roflumilast Cream (ZORYVE) – First PDE‑4 Topical for Atopic Dermatitis in Greater China

Gan & Lee Transfers MedTech Control to Hillhouse Investment, Accelerating Drug Delivery Innovation
CompanyDeals

Gan & Lee Transfers MedTech Control to Hillhouse Investment, Accelerating Drug Delivery Innovation